At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
The graduating cohort comprised seven batches across five specialized programs
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
Amitabh Dube and Sheetal Arora named Co-Chairmen for the forthcoming term
The approved product is therapeutically equivalent to Haldol tablets of Ortho McNeil Pharmaceutical
Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe (PFS) presentations
Built on Snowflake Cortex AI, the agent enables representatives to generate comprehensive pre-call plans through a single conversational interface
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
Targeting deadly drug-resistant acinetobacter infections
Subscribe To Our Newsletter & Stay Updated
